Chemoinformaics analysis of Malvadin-3-O-Alpha-L-Galactoside
| Molecular Weight | 487.481 | nRot | 6 |
| Heavy Atom Molecular Weight | 460.265 | nRig | 24 |
| Exact Molecular Weight | 487.16 | nRing | 4 |
| Solubility: LogS | -3.567 | nHRing | 2 |
| Solubility: LogP | 2.73 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 3 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 62 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 35 | No. of Aromatic Carbocycles | 2 |
| nHetero | 10 | No. of Aromatic Hetero Cycles | 1 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 27 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 25 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 16 |
| No. of Oxygen atom | 10 | No. of Arom Bond | 17 |
| nHA | 9 | APOL | 67.7734 |
| nHD | 6 | BPOL | 34.0306 |
| QED | 0.284 |
| Synth | 4.456 |
| Natural Product Likeliness | 1.946 |
| NR-PPAR-gamma | 0.865 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.003 |
| Pgp-sub | 0.951 |
| HIA | 0.62 |
| CACO-2 | -5.917 |
| MDCK | 0.00000612 |
| BBB | 0.09 |
| PPB | 0.909879 |
| VDSS | 1.021 |
| FU | 0.107687 |
| CYP1A2-inh | 0.053 |
| CYP1A2-sub | 0.093 |
| CYP2c19-inh | 0.011 |
| CYP2c19-sub | 0.141 |
| CYP2c9-inh | 0.001 |
| CYP2c9-sub | 0.376 |
| CYP2d6-inh | 0.037 |
| CYP2d6-sub | 0.245 |
| CYP3a4-inh | 0.006 |
| CYP3a4-sub | 0.052 |
| CL | 9.409 |
| T12 | 0.635 |
| hERG | 0.013 |
| Ames | 0.69 |
| ROA | 0.087 |
| SkinSen | 0.027 |
| Carcinogencity | 0.122 |
| EI | 0.013 |
| Respiratory | 0.072 |
| NR-Aromatase | 0.916 |
| Antiviral | Yes |
| Prediction | 0.90679 |